Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Sep;144(3):454-6.
doi: 10.1016/j.ajo.2007.04.011.

The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials

Abdhish R Bhavsar  1 , Michael S Ip, Adam R Glassman; DRCRnet and the SCORE Study Groups
Affiliations

The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials

Abdhish R Bhavsar et al. Am J Ophthalmol. 2007 Sep.

Abstract

Purpose: To report the incidence of endophthalmitis following intravitreal injection using a standardized injection procedure.

Design: Two randomized clinical trials.

Methods: Nonpreserved intravitreal triamcinolone acetonide in prefilled syringes (Allergan, Inc, Irvine, California, USA) was injected intravitreally in the Diabetic Retinopathy Clinical Research Network (DRCR net) and the Standard Care vs COrticosteroid for REtinal Vein Occlusion (SCORE) clinical trials. The standardized injection procedure did not include the use of topical antibiotics during the days prior to the injection.

Results: As of December 31, 2006, 1,378 intravitreal injections (538 eyes) have been administered in the Diabetic Retinopathy Clinical Research Network Diabetic Macular Edema trial and 631 injections (301 eyes) in Standard Care vs COrticosteroid for REtinal Vein Occlusion. There was one case of endophthalmitis in the 2,009 injections to date (0.05%, 95% confidence interval 0.001% to 0.277%).

Conclusion: A low rate of endophthalmitis is achievable using a standardized procedure for intravitreal injection without prescribing antibiotic prophylaxis on the days prior to the injection.

Trial registration: ClinicalTrials.gov NCT00105027 NCT00336323.

PubMed Disclaimer

References

    1. Scott IU, Flynn HW., Jr Reducing the risk of endophthalmitis following intravitreal injections. Retina. 2007;27:10–12. - PubMed
    1. Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology. 1991;98:1769–1775. - PubMed
    1. Ta CN, Egbert PR, Singh K, et al. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology. 2002;109:2036–2041. - PubMed
    1. Isenberg SJ, Apt L, Yoshimori R, et al. Chemical preparation of the eye in ophthalmic surgery. IV. Comparison of povidone-iodine on the conjunctiva with a prophylactic antibiotic. Arch Ophthalmol. 1985;103:1340–1342. - PubMed
    1. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–2816. - PubMed

Publication types

MeSH terms

Associated data